Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Abiraterone Acetate × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 32 Prostatic Neoplasms, Castration-Resistant 4 Urinary Bladder Neoplasms 1 Stage II Prostate Adenocarcinoma 1 Prostate Cancer Metastatic 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer 1 Dementia 1 Cognitive Dysfunction 1 Carcinoma, Transitional Cell 1 Adenocarcinoma 1

Interventions

fludrocortisone acetate 1 enzalutamide 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Radiosurgery 1 Prednisone 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Dexamethasone 1 Androgen Antagonists 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡